Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Arrowhead Pharmaceuticals (ARWR) over the last 10 years, with Sep 2025 value amounting to $733,000.

  • Arrowhead Pharmaceuticals' Gains from Investment Securities rose 110.77% to $733,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 60.04%. This contributed to the annual value of $814,000 for FY2025, which is 121.74% up from last year.
  • Arrowhead Pharmaceuticals' Gains from Investment Securities amounted to $733,000 in Q3 2025, which was up 696.74% from $92,000 recorded in Q1 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Gains from Investment Securities registered a high of $4.0 million during Q1 2024, and its lowest value of -$6.8 million during Q3 2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Gains from Investment Securities value was $48,000 (recorded in 2024), while the average stood at -$418,571.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Gains from Investment Securities plummeted by 228.23% in 2022, and later skyrocketed by 110.77% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $3.2 million in 2021, then plummeted by 228.23% to -$4.4 million in 2022, then reached -$999,000 in 2023, then spiked by 98.90% to -$11,000 in 2024, then spiked by 110.77% to $733,000 in 2025.
  • Its last three reported values are $733,000 in Q3 2025, $92,000 for Q1 2025, and -$11,000 during Q4 2024.